Odyssey Group International and Super Bowl MVPs Featured on “Banfield” Discussed Novel Concussion Treatment

Rhea-AI Summary

Odyssey Group International, Inc. (OTC: ODYY) recently featured on the show 'Banfield' to discuss their concussion treatment, PRV-002. Key figures from the Sports Advisory Board, including NFL legends Brett Favre, Kurt Warner, and Mark Rypien, highlighted the urgent need for effective concussion therapies. PRV-002, a synthetic neurosteroid, demonstrated strong preclinical results by improving neuroprotective effects and reducing brain injury symptoms. Odyssey aims to raise public awareness about concussions and plans to seek FDA approval for PRV-002.

Positive

• Appearance on 'Banfield' enhances visibility and public awareness of concussion treatment.
• PRV-002 demonstrated superior neuroprotective effects in preclinical studies.
• Collaboration with NFL legends may increase credibility and support.

Negative

• Dependence on successful FDA approval for PRV-002 poses risks.
• Potential funding challenges for development programs highlighted.

IRVINE, CA, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a health related company focused on developing unique, medical products including a treatment for concussion, recently appeared on “Banfield” with Ashleigh Banfield. The appearance included members of its Sports Advisory Board to discuss the prevalence of concussions and the potential treatment that the Company is developing. The recorded interview can be viewed below. 

Odyssey Group International Appearance on “Banfield” Video:
https://odysseygi.com/projects/brain-related-drug-development

VP of Drug Development, Jake VanLandingham, along with members of its Sports Advisory Board (SAB), including NFL legends Brett Favre, Kurt Warner and Mark Rypien discussed the need for a treatment for concussion and provided an overview of the Company’s drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion. The SAB supports Odyssey’s outreach efforts to enhance public awareness of concussion as well as the need for an FDA approved therapy.

About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com

About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.

Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to fund development programs, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies due to Covid, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

FAQ

What was discussed during Odyssey Group's appearance on 'Banfield'?

Odyssey Group discussed the urgency of developing effective concussion treatments and presented their drug candidate PRV-002.

What is PRV-002 and what are its benefits?

PRV-002 is a synthetic neurosteroid that has shown neuroprotective effects and reduced symptoms associated with concussions in preclinical studies.

Who participated in the discussion on concussions with Odyssey Group on 'Banfield'?

NFL legends Brett Favre, Kurt Warner, and Mark Rypien were part of the discussion.

What are the potential risks for Odyssey Group's PRV-002?

The development of PRV-002 relies on successful FDA approval, which presents a significant risk for the company.

How does Odyssey Group aim to increase awareness about concussions?

Odyssey Group is leveraging its Sports Advisory Board to promote public awareness regarding the need for FDA-approved concussion therapies.